Khiron Announces Grants of Options and Restricted Share Units
Khiron Life Sciences Corp. (KHRNF) announced the granting of 1,400,000 stock options and 950,000 restricted share units (RSUs) to its officers. These grants are subject to performance-based vesting conditions. The stock options have an exercise price of $0.75 per share and expire on November 23, 2026, while unvested RSUs will expire on December 15, 2024. This announcement follows shareholder approval of an amended restricted share unit plan. Khiron operates in Latin America and Europe, focusing on medical cannabis and leveraging telemedicine platforms.
- Granting of 1,400,000 stock options may motivate management and align interests with shareholders.
- 950,000 RSUs granted could enhance retention of key executives.
- Performance-based conditions may not translate into immediate value for shareholders if targets are not met.
TORONTO, Nov. 23, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the award of stock options ("Options") and restricted share units ("RSUs") under the Company's amended and restated restricted share unit plans approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020.
On November 23, 2021, the board of directors granted a total of 1,400,000 Options and 950,000 RSUs to certain officers of the Company. Certain of the Options and RSUs are subject to performance-based vesting conditions. The Options are exercisable at a price of
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Linkedin at
https://www.linkedin.com/company/khiron-life-sciences-corp/
Forward-Looking Statements
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Investor Contact:
Paola Ricardo
E: investors@khiron.ca
T: +1 (647) 556-5750
Media Contact:
Peter Leis
Europe Communications
E: pleis@khiron.ca
Carolina Gomez
Latam Communications
E: mgomez@khiron.ca
Khiron Europe:
Franziska Katterbach, President
E: fkatterbach@khiron.ca
View original content to download multimedia:https://www.prnewswire.com/news-releases/khiron-announces-grants-of-options-and-restricted-share-units-301431317.html
SOURCE Khiron Life Sciences Corp.
FAQ
What stock options did Khiron Life Sciences grant on November 23, 2021?
How many restricted share units were awarded by Khiron on November 23, 2021?
What is the expiration date for the stock options granted by Khiron?
When will the unvested restricted share units expire for Khiron?
What conditions are attached to Khiron's stock options and RSUs?
